High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug

📊 Investment Memo – argenx SE

1. Executive Summary

argenx is a commercial-stage biotech in immunology with an active blockbuster (VYVGART) and an advanced pipeline focused on rare autoimmune diseases. The investment thesis is based on:

• ✅ Leadership in a new therapeutic class (FcRn inhibitors)
• ✅ Very strong commercial growth (revenues doubled in 2 years)
• ✅ Pipeline with multiple near-term catalysts (2026–2027)
• ⚠️ Typical biotech risks: dependence on a single asset, pricing pressure, competition

2. Business Overview

• Global, commercial-stage company focused on immunology
• Proprietary platform: Immunology Innovation Program (IIP)
• Core product:
  • VYVGART (efgartigimod) – FcRn inhibitor

Pipeline includes:

• empasiprubart (C2 inhibitor)
• adimanebart (MuSK agonist)
• next-generation FcRn (ARGX-213, ARGX-124)

👉 Strategy: expand a single mechanism across multiple autoimmune indications

3. Financials and Performance

📈 Growth

• 2025 revenue: $4.15bn (+90% YoY)
• 2024: $2.19bn → 2023: $1.19bn

💰 Profitability

• Net income: $1.29bn
• EPS: $21.08
• Second consecutive profitable year

🧪 Costs

• R&D: $1.36bn
• SG&A: $1.37bn

👉 Interpretation:

• Commercial model already validated
• High reinvestment to sustain pipeline

4. Core Product: VYVGART

• Approved in 30+ countries
• Main indications:
  • gMG (generalized myasthenia gravis)
  • CIDP
  • ITP (Japan)
• Revenue concentration:
  • 78% in the U.S.
• Patient reach:
  • ~19,000 treated in 2025

👉 Insight:

• Single-product concentration risk, but with label expansion opportunity

5. Pipeline and Catalysts (2026 Outlook)

🎯 Key catalysts (12–24 months)

• Myositis Phase 3 → 3Q 2026
• ITP Phase 3 → 4Q 2026
• MMN (empasiprubart) → 4Q 2026
• Sjögren and CIDP → 2027

Other milestones:

• FDA decision (seronegative gMG): May 2026
• New trials (Graves’ disease, IgA nephropathy, etc.)

📊 Pipeline depth

• 10 ongoing registrational trials
• 4 new molecules added in 2025

👉 Insight:

• Strong optionality value
• Continuous catalyst flow

6. Strategy (Vision 2030)

Targets:

• 50,000 patients treated
• 10 approved indications
• 5 Phase 3 assets

Strategic priorities:

1. Expand VYVGART globally
2. Lead the FcRn class (next-gen + combinations)
3. Deliver next-generation immunology innovation

👉 Clear strategy: platform expansion + lifecycle management

7. Competitive Position

• Early leader in FcRn inhibitors
• Strong IP protection:
  • 500+ patents/applications
• Exclusivity:
  • ~2033 U.S. / 2032 EU for VYVGART

However:

• Intense competition in immunology:
  • monoclonal antibodies (mAbs)
  • small molecules
  • future biosimilars

8. Key Risks

📉 Commercial

• Dependence on a single product
• Pricing pressure (U.S., Europe, China)

🧪 Pipeline

• Clinical development risk (Phase 3 failures)
• Regulatory timing uncertainty

⚖️ Regulatory & Pricing

• U.S. IRA may reduce drug prices
• Reimbursement negotiations may compress margins

⚙️ Operational

• Reliance on third-party manufacturers

🔎 External Expansion (Market, Patients, Competition)

9. Market Size and Patients

gMG (core indication)

• Prevalence: ~20 per 100,000 → ~70–80k patients in the U.S.

CIDP

• ~42,000 patients in the U.S.

ITP

• ~72,000 patients in the U.S.

👉 Total core U.S. TAM >200k patients 👉 Global TAM significantly larger

💡 Insight: rare diseases → high pricing → high revenue per patient

10. Revenue Outlook (inferred)

Baseline:

• 2025: $4.1bn

Growth drivers:

• new indications
• geographic expansion
• adoption of subcutaneous / autoinjector formulations

👉 Reasonable mid-term scenario (2–4 years):

• $6–10bn potential revenue range

11. Competition

Direct (FcRn inhibitors)

• UCB – rozanolixizumab
• Johnson & Johnson / Momenta
• AstraZeneca

Indirect

• IVIg (current standard of care)
• Rituximab, corticosteroids
• therapies from big pharma (Roche, Novartis, AbbVie)

👉 Insight:

• FcRn = emerging market
• first-mover advantage, but increasing competition

🧠 Investment Conclusion

Bull Case

• Strong, proven revenue growth
• Scalable platform across indications
• Pipeline with multiple catalysts
• Leadership in a novel therapeutic class

Bear Case

• High dependence on one product
• Pricing/regulatory pressure may erode margins
• High pipeline risk (typical biotech)
• Increasing competition

📌 Final Take

👉 Profile: High-growth biotech compounding story 👉 Investment type:

• Growth + clinical optionality
• High volatility

👉 Core thesis:

• If VYVGART becomes a multi-indication platform drug → significant upside
• If pipeline fails or pricing pressure intensifies → material downside risk